Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Temsirolimus|DRUG: Cisplatin|DRUG: Erlotinib
Sponsor: Columbia University
Collaborators: Wyeth is now a wholly owned subsidiary of Pfizer|Genentech, Inc.